Provided herein are anti-fibrotic compounds, in particular those of Formula (I), that inhibit the TGF-beta signaling pathway. Also provided are pharmaceutical compositions comprising the anti-fibrotic compounds, and methods of treating diseases or conditions associated with fibrosis, inflammation, and benign or malignant neoplastic diseases in a subject by administering a compound or composition described herein.

Methods, systems, and computer readable media may be operable to facilitate an anticipation of an execution of a process termination tool. An allocation stall counter may be queried at a certain frequency, and from the query of the allocation stall counter, a number of allocation stall counter increments occurring over a certain duration of time may be determined. If the number of allocation stall counter increments is greater than a threshold, a determination may be made that system memory is running low and that an execution of a process termination tool is imminent. In response to the determination that system memory is running low, a flag indicating that system memory is running low may be set, and one or more programs, in response to reading the flag, may free memory that is not necessary or required for execution.

Methods, systems, and computer readable media may be operable to facilitate an anticipation of an execution of a process termination tool. An allocation stall counter may be queried at a certain frequency, and from the query of the allocation stall counter, a number of allocation stall counter increments occurring over a certain duration of time may be determined. If the number of allocation stall counter increments is greater than a threshold, a determination may be made that system memory is running low and that an execution of a process termination tool is imminent. In response to the determination that system memory is running low, a flag indicating that system memory is running low may be set, and one or more programs, in response to reading the flag, may free memory that is not necessary or required for execution.

The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.

The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

##STR00001##

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is described, wherein the substituents are as defined herein. Pharmaceutical compositions comprising the same and method of using the same are also described.

##STR00001##

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R  (I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II):

##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, R.sup.4, R.sup.6a, R.sup.6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (II):

##STR00001## including stereoisomers and pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.3, R.sup.4, R.sup.6a, R.sup.6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.